285 related articles for article (PubMed ID: 28816076)
1. Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.
Li H; Chintalapudi SR; Jablonski MM
Expert Opin Investig Drugs; 2017 Oct; 26(10):1103-1114. PubMed ID: 28816076
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatment of atrophic age-related macular degeneration.
Mata NL; Vogel R
Curr Opin Ophthalmol; 2010 May; 21(3):190-6. PubMed ID: 20216419
[TBL] [Abstract][Full Text] [Related]
3. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
Tolentino MJ; Dennrick A; John E; Tolentino MS
Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
[TBL] [Abstract][Full Text] [Related]
4. The genetics of age-related macular degeneration (AMD)--Novel targets for designing treatment options?
Grassmann F; Fauser S; Weber BH
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):194-202. PubMed ID: 25986585
[TBL] [Abstract][Full Text] [Related]
5. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS; Schmidt-Erfurth U; van Lookeren Campagne M; Henry EC; Brittain C
Retina; 2017 May; 37(5):819-835. PubMed ID: 27902638
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ; Tolentino AJ
Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
[TBL] [Abstract][Full Text] [Related]
7. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
8. Dry Age-Related Macular Degeneration Pharmacology.
Wright CB; Ambati J
Handb Exp Pharmacol; 2017; 242():321-336. PubMed ID: 27900609
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic targets in atrophic age-related macular degeneration.
Petrukhin K
Expert Opin Ther Targets; 2007 May; 11(5):625-39. PubMed ID: 17465722
[TBL] [Abstract][Full Text] [Related]
10. Current therapeutic developments in atrophic age-related macular degeneration.
Hanus J; Zhao F; Wang S
Br J Ophthalmol; 2016 Jan; 100(1):122-7. PubMed ID: 26553922
[TBL] [Abstract][Full Text] [Related]
11. Update on geographic atrophy in age-related macular degeneration.
Biarnés M; Monés J; Alonso J; Arias L
Optom Vis Sci; 2011 Jul; 88(7):881-9. PubMed ID: 21532519
[TBL] [Abstract][Full Text] [Related]
12. The complement system: a novel therapeutic target for age-related macular degeneration.
Shughoury A; Sevgi DD; Ciulla TA
Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for age-related macular degeneration.
Augustin AJ; Offermann I
Expert Opin Emerg Drugs; 2006 Nov; 11(4):725-40. PubMed ID: 17064228
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the management of dry age-related macular degeneration: A review.
Bandello F; Sacconi R; Querques L; Corbelli E; Cicinelli MV; Querques G
F1000Res; 2017; 6():245. PubMed ID: 28529701
[TBL] [Abstract][Full Text] [Related]
16. Antibody therapies and their challenges in the treatment of age-related macular degeneration.
Volz C; Pauly D
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):158-72. PubMed ID: 25725263
[TBL] [Abstract][Full Text] [Related]
17. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
Borchert GA; Shamsnajafabadi H; Hu ML; De Silva SR; Downes SM; MacLaren RE; Xue K; Cehajic-Kapetanovic J
Cells; 2023 Aug; 12(16):. PubMed ID: 37626902
[TBL] [Abstract][Full Text] [Related]
18. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
[TBL] [Abstract][Full Text] [Related]
19. Regulatory aspects of drug approval for macular degeneration.
Gryziewicz L
Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706
[TBL] [Abstract][Full Text] [Related]
20. New Treatment Modalities for Geographic Atrophy.
Kandasamy R; Wickremasinghe S; Guymer R
Asia Pac J Ophthalmol (Phila); 2017; 6(6):508-513. PubMed ID: 28905539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
